Don't Forget To
Rate This Article

Summit Therapeutics Inc. (SMMT:NASDAQ). {TLSR} -- Placeholder sh
Trending Company

(12/6/22)

aaa

ddd

Co. Reports Positive Results in Phase 2b/3 Alzheimer's Trial
Source: Streetwise Reports (12/05/2022)

Shares of Anavex Life Sciences Corp. traded 36% higher Friday after the company reported that during a Phase 2b/3 clinical trial of patients diagnosed with early Alzheimer's disease, its ANAVEX®2-73 (blarcamesine) met both key primary and secondary endpoints and demonstrated significant reductions in clinical decline.

Target Price Boosted on Canadian Pharma Co.
Source: Dr. Andre Uddin (11/30/2022)

This company, undergoing a business model shift, is doing well and remains Buy rated despite a weaker-than-expected Q3/22, noted a Research Capital Corp. report.

Major Contract and Faster Commercialization for Chemicals Co.
Source: Penny Queen (11/29/2022)

Since hitting the market on November 10, 2022, ASP Isotopes has been busy and has now announced a US$675 million-dollar contract. Expert Penny Queen shares this news and reviews why she still believes this company is worthwhile.

Biopharma Co. Now at a Bargain Price, Analyst Says
Source: Dr. Andrew Uddin (11/29/2022)

Recent share price weakness and a catalyst-rich next six months are good news for investors, noted a Research Capital Corp. report.

Biopharma Co. Trades to New 52-Week High
Source: Streetwise Reports (11/28/2022)

Shares of Axsome Therapeutics Inc. traded to a new 52-week high after the company reported its AXS-05 successfully met both the primary and key secondary endpoints in the Phase 3 ACCORD Alzheimer's disease agitation trial.